Introduction
Leading biosimilars company expands partnership with Civica to introduce Insulin Glargine in the U.S., enhancing access to affordable diabetes treatments while retaining full manufacturing and intellectual property rights.
Also Read: Hero MotoCorp: Stock Jumps After Company Expands in 50 Countries
Share price movement of Biocon
On October 17, 2025, Biocon Ltd opened at ₹360.05, up 0.55% from its previous close of ₹358.10. The stock reached a high of ₹361.15 (0.87%) and a low of ₹354.95. By 1:41 PM, it traded at ₹355.60, down 0.70%, with a market cap of ₹47,542.43 crore.
Biocon Biologics and Civica Launch Insulin Glargine
Biocon Biologics Ltd. and Civica, Inc. have expanded their partnership to launch a new Insulin Glargine medicine in the U.S. This will increase affordable insulin supply for diabetes patients.
The agreement allows Biocon Biologics to manufacture Insulin Glargine. Civica will distribute and sell it under its own label, including the CalRx brand in California. No technology transfer is involved.
Biocon Biologics retains all intellectual property and marketing rights. The medicine complements Biocon Biologics’ existing FDA-approved interchangeable Insulin Glargine-yfgn. Financial and additional terms of the multi-year agreement were not disclosed.
Stock performance of Biocon for Period of 1 week, 6 months, and 1 year
Biocon Ltd delivered a 1.34% return over the past week. The stock gained 8.12% in the past six months and 5.65% over the past year.
Also Read: KRN Heat Exchanger: Stock jumps after it commences production of its Bus AC Division
Shareholding pattern of Biocon
| Particulars | Jun 2025 | Mar 2025 | Dec 2024 |
| Promoter | 54.50% | 60.60% | 60.60% |
| FII | 7.00% | 5.70% | 5.70% |
| DII | 21.50% | 15.70% | 15.40% |
| Public | 16.90% | 17.80% | 18.10% |
About Biocon
Biocon Biologics Limited (NSE: BIOCON) is a global biosimilars company serving 6+ million patients across 120+ countries, offering 10 commercialized biosimilars and a 20-asset pipeline, advancing healthcare access and ESG initiatives.
Stay Ahead with the Latest Stock Market Updates – Click Here
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
FAQs
A: Biocon Biologics Ltd. share price is rising after expanding partnership with Civica to launch Insulin Glargine in the U.S.
A: Biocon Biologics Ltd. stock has a 52-week high of ₹405.90 and a 52-week low of ₹290.80.
A: Biocon Biologics Ltd. operates in the global biosimilars, diabetology, oncology, immunology, ophthalmology, and other healthcare sectors.
